Spots Global Cancer Trial Database for Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Official Title: A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

Study ID: NCT01717482

Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Interventions

Metformin

Placebo Comparator

Study Description

Brief Summary: The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Detailed Description: Participants will need to be scheduled to undergo a surgical resection of their lung cancer at the Mayo Clinic in Rochester, Minnesota. They will be asked to provide a blood sample prior to their surgery. Samples of tumor tissue and normal lung tissue will be taken from the samples removed during your lung surgery. The tissue will be used to evaluate DNA. A skin biopsy at the edge of the incision that has already been made will be done during your surgery. We will take the skin and grow skin fibroblasts. Then we will reprogram the skin fibroblasts into induced pluripotent cells. You will be "randomized" into one of the study groups to either take Metformin for 6 months with your standard of care follow up or to receive standard of care follow up.